Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Stock Information for Lexicon Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.